Dear All (and with thanks to Kevin for co-authoring): Yesterday saw the release of a major new report on Pull incentives from Canada! The report’s cover art eloquently summarizes its key message: Well said … and proves that a picture really is worth 1,000 words! Here are the links you’ll need: The report’s webpage at the
Dear All, Expanding the available Push funding, the EU’s HERA (Health Emergency Preparedness and Response Authority) has created HERA Invest by allocating €100m in support early and late phases of clinical trials. HERA Invest is open on a rolling application basis to EU-based SMEs developing medical countermeasures that address one of the following cross-border health threats: (i)
Dear All, Summer is coming to a close … hard to believe it’s almost September! To get you going for the fall, the ENABLE-2 consortium has announced a call to support hit-to-lead compound development by researchers at publicly-funded European universities. The call is focused on molecules with the potential to be direct-acting therapies for one or more of the following
Dear All, As a follow up the 19 Aug 2023 newsletter on MHLW’s work on Pull incentives (and with thanks to Yann Ferrise of GARDP for pointing out this out), we have an update in the 7 Aug 2023 edition of Nikkan Yakugyo (https://nk.jiho.jp/article/183026). It’s in Japanese and so again I must apologize for my lack
Dear All, Some great news today! We have visible evidence of global government action in support of the addressing our antibiotic gaps. First, CARB-X has announced that Canada has now joined its coalition of funders with a pledge of $6.3m! Woot, woot! Go Team Canada! Second, the UK and Germany have renewed their funding support with commitments of GBP
Dear All, A recent paper by Hasegawa et al. and a multi-paper supplement, both in Clinical Infectious Diseases, combine to provide an interesting message. First, the paper by Hasegawa and colleagues. I’ve taken the title of this newsletter from an accompanying editorial by MacDougall who opens his commentary with “If there is one thing infectious
Dear All, The WHO is looking for a consultant to develop a campaign to prevent non-prescription antibiotic sales! This 4-month contract sounds intriguing to say the least. This position is tied into (and culminates with) the annual World AMR Awareness Week — it’s interesting to see how the WHO is working to prevent this problem! Lots of
Dear All (and with thanks to Kevin for co-authoring), The UK NHS England Pilot is known to us all as the first real attempt at an antibiotic subscription model and now it will be undergoing a major overhaul. In case you are a new reader or would like a refresher on the pilot, here are the links
Dear All, During their recent turn to hold the EU presidency (1 Jan to 30 Jun 2023), the Swedes have steadily pushed AMR as one of their top priorities. As part of this, Sweden used their most recent presidency to release a motion to adopt a Council Recommendation on fighting AMR. Here are the parallel links that
Dear All, I wrote in 2018 about National Cancer Institute’s Natural Products Branch (NPB) and its program for Natural Product Discovery (NPNPD) as a resource for antimicrobial discovery. In brief, it’s a global collection of natural products that is available as a library of semi-pure natural product samples that comes pre-platted in 384-well plates. The deep idea behind
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust